Solid-phase enzyme immunoassay of terminal deoxynucleotidyl transferase evaluated.
We evaluated a newly developed solid-phase immunoassay (EIA) of terminal deoxynucleotidyl transferase (TdT, EC 2.7.7.3) and compared it with the enzymatic assay of TdT involving DNA polymerase. We assessed the precision, performance characteristics, and clinical efficacy of the EIA procedure, using 249 specimens of peripheral blood and bone marrow and 118 specimens of whole blood. On linear regression analysis of results for these 249 samples as measured by the two procedures, the correlation coefficient was 0.87. Distribution of TdT in mononuclear cells isolated from whole blood and bone marrow of subjects in several disease categories indicated good concordance between the two assay procedures. The EIA procedure is precise, can be performed on whole blood without first isolating mononuclear cells, is nonisotopic, and shows potential as a quantitative indicator for the differential diagnosis and monitoring of human leukemia.
D001853:Bone Marrow / Q000201:enzymology; D004253:DNA Nucleotidylexotransferase / Q000032:analysis*; D004254:DNA Nucleotidyltransferases / Q000032:analysis*; D004259:DNA-Directed DNA Polymerase; D005069:Evaluation Studies as Topic; D006801:Humans; D007124:Immunoenzyme Techniques; D007945:Leukemia, Lymphoid / Q000201:enzymology; D007951:Leukemia, Myeloid / Q000201:enzymology; D008214:Lymphocytes / Q000201:enzymology; D008223:Lymphoma / Q000201:enzymology; D012016:Reference Values; D013223:Statistics as Topic
D004254:DNA Nucleotidyltransferases; D004253:DNA Nucleotidylexotransferase; D004259:DNA-Directed DNA Polymerase